{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:59:17Z","timestamp":1740113957545,"version":"3.37.3"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Roche and AstraZeneca"},{"name":"Chugai Pharmaceutical Co., Ltd"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.lungcan.2018.10.005","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T03:05:34Z","timestamp":1538795134000},"page":"230-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-5343","authenticated-orcid":false,"given":"Tomohito","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Tsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuaki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Ryota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Takeyasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento J.","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yanagimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayasu","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Murakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2018.10.005_bib0005","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"KEYNOTE-024 investigators, pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.10.005_bib0010","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2018.10.005_bib0015","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.10.005_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.10.005_bib0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jamaoncol.2015.4685","article-title":"PD-L1 testing in cancer: challenges in companion diagnostic development","volume":"2","author":"Hansen","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.lungcan.2018.10.005_bib0030","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2018.10.005_bib0035","doi-asserted-by":"crossref","first-page":"20090","DOI":"10.1038\/srep20090","article-title":"Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer","volume":"6","author":"Sheng","year":"2016","journal-title":"Sci. Rep."},{"year":"2015","series-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","author":"Travis","key":"10.1016\/j.lungcan.2018.10.005_bib0040"},{"year":"2011","series-title":"TNM Classification of Malignant Tumours","author":"Sobin","key":"10.1016\/j.lungcan.2018.10.005_bib0045"},{"key":"10.1016\/j.lungcan.2018.10.005_bib0050","series-title":"Wiley, Encyclopedia of Clinical Trials","article-title":"Assessment bias","author":"G\u00f8tzsche","year":"2007"},{"year":"2017","series-title":"IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer","author":"Tsao","key":"10.1016\/j.lungcan.2018.10.005_bib0055"},{"year":"2007","series-title":"Guidance for Industry and FDA Staff: Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests","author":"US FDA","key":"10.1016\/j.lungcan.2018.10.005_bib0060"},{"key":"10.1016\/j.lungcan.2018.10.005_bib0065","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1158\/1078-0432.CCR-16-2375","article-title":"Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer","volume":"23","author":"Ratcliffe","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2018.10.005_bib0070","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"Multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.lungcan.2018.10.005_bib0075","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.2017.74.7642","article-title":"Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer","volume":"35","author":"Buttner","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.005_bib0080","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/modpathol.2017.59","article-title":"PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability","volume":"30","author":"Brunnstr\u00f6m","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lungcan.2018.10.005_bib0085","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jtho.2017.11.112","article-title":"Comparison of Four PD-L1 immunohistochemical assays in lung cancer","volume":"13","author":"Hendry","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.005_bib0090","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/modpathol.2016.117","article-title":"Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas","volume":"29","author":"Scheel","year":"2016","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lungcan.2018.10.005_bib0095","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/his.13375","article-title":"Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer","volume":"72","author":"Scheel","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2018.10.005_bib0100","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218305890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218305890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T06:08:38Z","timestamp":1589954918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218305890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":20,"alternative-id":["S0169500218305890"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.005","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}